Comparison of the pharmacokinetics of porcine calcitonin in saline and in gelatin diluents in healthy volunteers

  • S. G. Brooks
  • K. R. Butterworth
  • R. B. Christie
  • J. Fox
Original papers


A randomised 2-way crossover study was carried out in nine healthy male volunteers to compare the pharmacokinetics of porcine calcitonin (pCT) following i.m. administration of 160 i.u. of pCT in physiological saline or in a solution of hydrolysed gelatin.

A new radioimmunoassay for pCT is described. It employs an antiserum raised in a guinea pig and a labelled tracer prepared from highly purified pCT.

While comparable mean areas under the scrum concentration-time curve for both dosage forms indicate equivalent bioavailability, the serum pCT profiles were different; peak pCT levels of 8.3±0.8 ng ml−1 (s.e.m.) occurred at 13±2 min (s.e.m.) with peak levels of 4.8±0.5 ng ml−1 (s.e.m.) when the gelatin diluent was used.

The hypocalcaemic effects produced by the two preparations of pCT were of short duration (¹h) and of a similar magnitude (−0.08 to −0.12 mmol.l−1). Comparable degrees of hypophosphataemia (−0.11 to −0.15 mmol.l−1) were observed 20 min post-injection.

The administration of pCT in gelatin and saline diluents resulted in markedly different pharmacokinetic profiles. Whether there are therapeutic advantages in the use of either diluent remains to be investigated.

Key words

Calcitonin pharmacokinetics saline and gelatin diluents hypocalcaemia and hypophosphataemia 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schieuter R..I., Caldwell A. (1967): Thyrocalcitonin: Parameters of Bioassay. Endocrinology. 81 854–860.CrossRefGoogle Scholar
  2. 2.
    Hirsch P., Munson R. (1969). Thyrocalcitonin. Physiol. Rev.. 49, 548–622.PubMedGoogle Scholar
  3. 3.
    Aldred J.P., Clements G.C., Schleuler R.J., Bastian J.W., Dailey J.P., Wazeter F.X. (1967): Pharmacologic and toxicologic effects of porcine thyrocalcitonin in animals. Fed. Proc. 26. 373–378.Google Scholar
  4. 4.
    Martin T.J. (1978): The therapeutic uses of calcitonin. Scott. Med. J., 23. 161–165.PubMedGoogle Scholar
  5. 5.
    Foster G.V., Gudmundsson T.V., Joplin G.F., Martin T.J.. Melvin K.E.W., Thalassinos N., Fraser T.R., Maclntyre I. (1967): In: Calcitonin. Proceedings of the symposium on thyrocalcitonin and the ’C cells. London. Heinemann 379–384.Google Scholar
  6. 6.
    Milhaud G., Job J.C. (1966): Thyrocalcitonin: effect on idiopathic hypercalcaemia. Science, 154, 794–795.CrossRefPubMedGoogle Scholar
  7. 7.
    Riggs L., Arnaud CD., Goldsmith R.S., Taylor W.F., McCall J.T., Sessler A.D. (1971): Plasma kinetics and acute effects of pharmacological doses of porcine calcitonin in man. J. Clin. Endocrinol., 33. 115–127.CrossRefGoogle Scholar
  8. 8.
    Heath H., Sizemore G.W. (1982): Radioimmunoassay for calcitonin. Clin. Chem., 28.1219–1226.PubMedGoogle Scholar
  9. 9.
    Hills M., Armilage P. (1979): The two-period crossover clinical trial. Br. J. Clin. Pharmacol., 8. 7–20.PubMedGoogle Scholar
  10. 10.
    Westlake W.J. (1972): Use of confidence intervals in analysis of comparative bioavailability trials. J. Pharm. Sci., 61. 1340–1341.CrossRefPubMedGoogle Scholar
  11. 11.
    Glick I.W., Friedman M. (1969): High-dosage, short-term corticotrophin therapy in acute asthma. Thorax. 24. 415–420.CrossRefPubMedGoogle Scholar
  12. 12.
    Neer R.M., Parsons J.A., Krane S.M., Deftos L.J., Shields C.L., Copp D.H., Potts Jr. J.T. (1969): In: Calcitonin. Proceedings of the 2nd International Symposium. London. Heinemann, pp 547–554.Google Scholar
  13. 13.
    Vigo P.L., Milhaud G., Peracchi M., Girardello R., Ortolani S., Polli E.E. (1980): Plasma immunoreactive N-terminal parathyroid hormone and cyclic AMP and cyclic GMP urinary levels in man after i.m. administration of two different doses of porcine calcitonin. Biomedicine. 33. 255–259.PubMedGoogle Scholar
  14. 14.
    Wener J.A., Gorton S.J., and Raisz L.G. (1972): Escape from inhibition of resorption in cultures of foetal bone treated with calcitonin and parathyroid hormone. Endocrinology. 90. 752–759.CrossRefPubMedGoogle Scholar
  15. 15.
    Moffatt W.H., Morrow J., Simpson N. (1974): Effects of calcitonin therapy in deafness associated with Paget’s disease of bone. Br. Med. J., 4. 203–204.CrossRefPubMedGoogle Scholar
  16. 16.
    West T., Joffe M., Sinclair L., O’Riordan J. (1971): Treatment of hypercalcaemia with calcitonin. Lancet i. 675–678.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • S. G. Brooks
    • 1
  • K. R. Butterworth
    • 2
  • R. B. Christie
    • 1
  • J. Fox
    • 3
  1. 1.Rorer Health Care LtdSussexUK
  2. 2.The British Industrial Biological Research AssociationCarshaltonUK
  3. 3.Department of Animal Physiology and NutritionUniversity of LeedsLeedsUK

Personalised recommendations